2023年2月2日

明尼阿波利斯，2023年2月2日/美通社/——Bio-Techne Corporation(納斯達克代碼:TECH)宣布，其董事會決定在截至2022年12月31日的季度支付每股0.08美元的股息。季度股息將於2023年2月27日支付給2023年2月13日登記的所有普通股股東。未來的現金股利將由董事會按季度審議。生物科技公司(納斯達克代碼:TECH)是一家全球性的生命科學公司，為研究和臨床診斷界提供創新工具和生物活性試劑。生物技術產品有助於對生物過程和特定疾病的性質和進展進行科學調查。它們有助於藥物發現工作，並為準確的臨床測試和診斷提供手段。Bio-Techne擁有數千種產品，在2022財年的淨銷售額約為11億美元，在全球擁有約3000名員工。更多關於Bio-Techne及其品牌的信息，請訪問www.bio techne.com。前瞻性陳述:我們的新聞稿可能包含《私人證券訴訟改革法案》所指的前瞻性陳述。這些報表涉及可能影響業務實際結果的風險和不確定性。 Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues resulting from the COVID-19 pandemic, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships. For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.